Study analysis · PeerJ · 2024
A protein normally found only in muscle is hijacked by colorectal cancer to fuel its growth, and it could be a new way to predict patient survival.
A protein called CKMT2 is higher in colorectal cancer, helps it grow by making it use more sugar, and tells us that patients with higher levels tend to live shorter lives.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study examined tissue samples from 220 people with colorectal cancer and found that a protein called CKMT2 is higher in cancer tissue and linked to worse outcomes. They also did experiments in cells to explore how it might work. However, this kind of study can only show that things are related, not that one thing directly causes the other—like finding that ice cream sales go up when it's hot doesn't mean ice cream causes the heat.
What’s the bottom line?
Scientists found that a protein named CKMT2 is more active in colorectal cancer cells than in normal cells. Patients with high CKMT2 had worse survival. In lab experiments, blocking CKMT2 slowed cancer cell movement and increased cell death.
How strong is this study?
The researchers did a good job by carefully collecting data from patients and using multiple methods to check their results, like looking at both tissues and cells. But because they only studied people from one hospital and didn't change anything in the patients (just observed), we can't be totally sure the protein is the cause. It's like watching a video of a plant growing—you see what happens, but you don't know if giving it more water would make it grow faster.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
35 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=220)+13.3/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design cannot establish causation due to potential unmeasured confounders. In vitro experiments provide mechanistic hypotheses but do not confirm causality in humans. The study only demonstrates associations and correlations.
No Conflicts
No conflicts of interest identified
No conflicts of interest are disclosed or apparent from the text.
The study lacks explicit conflict of interest and funding statements. The authors' affiliations are not provided, and only institutional ethical approval is noted.
Key takeaways
- 01
In 220 patients, CKMT2 was higher in cancer tissue (score 1.60 vs 0.45).
- 02
High CKMT2 linked to shorter survival.
- 03
In cells, reducing CKMT2 decreased migration by ~50% and increased apoptosis.
- 04
Yes, the difference in survival is clinically meaningful (median survival ~27 vs 34 months).
Surprising findings
- CKMT2, a protein typically restricted to skeletal and heart muscle, is highly expressed in colorectal cancer and promotes tumor growth.It's counterintuitive that a muscle-specific energy metabolism protein would be hijacked by cancer cells, suggesting tumors can co-opt specialized metabolic machinery for their own benefit.
- CKMT2 expression correlates with the Warburg effect through a direct interaction with LDHB, not with LDHA typically associated with cancer glycolysis.Many cancers upregulate LDHA, not LDHB. This study shows CKMT2 specifically boosts LDHB, which is less commonly reported in cancer, revealing a new metabolic vulnerability.
Practical takeaways
If you have colorectal cancer, ask your doctor if CKMT2 testing is available to better understand your prognosis, especially if standard markers like CEA are borderline.
This test is not yet clinically standard; it's research-grade. The study used a specific immunohistochemistry assay not widely available.
medium confidenceFor researchers: Consider CKMT2 as a novel target for developing drugs that disrupt the Warburg effect in colorectal cancer.
Only one cell line (SW480) was tested; efficacy in other CRC subtypes is unknown. In vivo animal studies are needed.
low confidenceFor diet/lifestyle: While no direct application, understanding that creatine metabolism fuels tumors might caution against creatine supplements in cancer patients.
This is a speculative leap; the study did not test creatine supplementation. The link is indirect through CKMT2.
very low confidenceWhy this study matters
CKMT2 is elevated in colorectal cancer and linked to worse outcomes
In 220 patients, CKMT2 protein levels were significantly higher in cancer tissue (mean score 1.60) compared to nearby healthy tissue (0.45) (p < 0.001). High CKMT2 expression was associated with shorter overall survival: average 27.6 months vs 34.3 months for low expression (log-rank p < 0.001). Multivariate analysis confirmed CKMT2 as an independent prognostic factor (HR = 1.93, 95% CI 1.09–3.43).
This suggests CKMT2 could help doctors identify patients who need more aggressive treatment, potentially improving survival predictions beyond standard factors like tumor stage.
CKMT2 fuels cancer by boosting the Warburg effect
Silencing CKMT2 in SW480 colorectal cancer cells decreased glucose consumption and lactate production—hallmarks of aerobic glycolysis (Warburg effect). The mechanism involves CKMT2 physically interacting with and upregulating LDHB, an enzyme that converts pyruvate to lactate, thereby accelerating glycolysis.
The Warburg effect is a key feature of many cancers. Understanding how CKMT2 drives this process might lead to new drugs that cut off the cancer's energy supply.
CKMT2 silencing reduces cancer cell migration and increases death
In lab experiments, turning off CKMT2 in SW480 cells reduced cell migration by about 50% (p < 0.001) and increased apoptosis (cell death) significantly (p < 0.001). This shows CKMT2 is not just a marker but actively helps cancer spread and survive.
These functional effects point to CKMT2 as a potential therapeutic target. If we can block CKMT2, we might slow cancer spread and make it more responsive to treatment.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that a protein named CKMT2 is more active in colorectal cancer cells than in normal cells. Patients with high CKMT2 had worse survival. In lab experiments, blocking CKMT2 slowed cancer cell movement and increased cell death.
Research results
In 220 patients, CKMT2 was higher in cancer tissue (score 1.60 vs 0.45). High CKMT2 linked to shorter survival. In cells, reducing CKMT2 decreased migration by ~50% and increased apoptosis.
What this means - more context
Yes, the difference in survival is clinically meaningful (median survival ~27 vs 34 months).
To investigate the clinical significance, biological functions, and molecular mechanisms of CKMT2 in colorectal cancer (CRC).
CKMT2 is highly expressed in CRC tissues and cell lines, correlates with poor prognosis, and promotes CRC growth and progression by enhancing the Warburg effect through interaction with LDHB.
Methods Used
Immunohistochemistry on 220 CRC patients; qRT-PCR, western blot, cell migration/apoptosis assays, and co-immunoprecipitation in SW480 cells.
Main Finding
CKMT2 overexpression in CRC (mean score 1.60 vs 0.45, p<0.001) is an independent prognostic factor (HR=1.929, 95% CI 1.086–3.426, p=0.025). Silencing CKMT2 reduces migration and increases apoptosis; CKMT2 interacts with LDHB to upregulate glycolysis.
Confidence Level
Moderate: prospective cohort with 220 patients, but single-center; in vitro experiments support mechanism, but further validation needed.
Study Flags
Red Flags
- •Single-center study with potential selection bias
- •No randomization or blinding in cohort analysis
- •Mechanistic findings only in one cell line (SW480)
Surprising Findings
CKMT2, a protein typically restricted to skeletal and heart muscle, is highly expressed in colorectal cancer and promotes tumor growth.
It's counterintuitive that a muscle-specific energy metabolism protein would be hijacked by cancer cells, suggesting tumors can co-opt specialized metabolic machinery for their own benefit.
Practical Takeaways
If you have colorectal cancer, ask your doctor if CKMT2 testing is available to better understand your prognosis, especially if standard markers like CEA are borderline.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study examined tissue samples from 220 people with colorectal cancer and found that a protein called CKMT2 is higher in cancer tissue and linked to worse outcomes. They also did experiments in cells to explore how it might work. However, this kind of study can only show that things are related, not that one thing directly causes the other—like finding that ice cream sales go up when it's hot doesn't mean ice cream causes the heat.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Prospective design with consecutive enrollment
- Use of multivariable Cox regression to adjust for confounders
- Inclusion of both tissue and cell line experiments to explore mechanisms
Weaknesses
- Observational design cannot exclude residual confounding
- Relatively small sample size (220 patients)
- Single-center study, limiting external validity
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists found that a protein named CKMT2 is more active in colorectal cancer cells than in normal cells. Patients with high CKMT2 had worse survival. In lab experiments, blocking CKMT2 slowed cancer cell movement and increased cell death.
Research results
In 220 patients, CKMT2 was higher in cancer tissue (score 1.60 vs 0.45). High CKMT2 linked to shorter survival. In cells, reducing CKMT2 decreased migration by ~50% and increased apoptosis.
What this means - more context
Yes, the difference in survival is clinically meaningful (median survival ~27 vs 34 months).
To investigate the clinical significance, biological functions, and molecular mechanisms of CKMT2 in colorectal cancer (CRC).
CKMT2 is highly expressed in CRC tissues and cell lines, correlates with poor prognosis, and promotes CRC growth and progression by enhancing the Warburg effect through interaction with LDHB.
Methods Used
Immunohistochemistry on 220 CRC patients; qRT-PCR, western blot, cell migration/apoptosis assays, and co-immunoprecipitation in SW480 cells.
Main Finding
CKMT2 overexpression in CRC (mean score 1.60 vs 0.45, p<0.001) is an independent prognostic factor (HR=1.929, 95% CI 1.086–3.426, p=0.025). Silencing CKMT2 reduces migration and increases apoptosis; CKMT2 interacts with LDHB to upregulate glycolysis.
Confidence Level
Moderate: prospective cohort with 220 patients, but single-center; in vitro experiments support mechanism, but further validation needed.
Study Flags
Red Flags
- •Single-center study with potential selection bias
- •No randomization or blinding in cohort analysis
- •Mechanistic findings only in one cell line (SW480)
Surprising Findings
CKMT2, a protein typically restricted to skeletal and heart muscle, is highly expressed in colorectal cancer and promotes tumor growth.
It's counterintuitive that a muscle-specific energy metabolism protein would be hijacked by cancer cells, suggesting tumors can co-opt specialized metabolic machinery for their own benefit.
Practical Takeaways
If you have colorectal cancer, ask your doctor if CKMT2 testing is available to better understand your prognosis, especially if standard markers like CEA are borderline.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study examined tissue samples from 220 people with colorectal cancer and found that a protein called CKMT2 is higher in cancer tissue and linked to worse outcomes. They also did experiments in cells to explore how it might work. However, this kind of study can only show that things are related, not that one thing directly causes the other—like finding that ice cream sales go up when it's hot doesn't mean ice cream causes the heat.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Prospective design with consecutive enrollment
- Use of multivariable Cox regression to adjust for confounders
- Inclusion of both tissue and cell line experiments to explore mechanisms
Weaknesses
- Observational design cannot exclude residual confounding
- Relatively small sample size (220 patients)
- Single-center study, limiting external validity
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did a good job by carefully collecting data from patients and using multiple methods to check their results, like looking at both tissues and cells. But because they only studied people from one hospital and didn't change anything in the patients (just observed), we can't be totally sure the protein is the cause. It's like watching a video of a plant growing—you see what happens, but you don't know if giving it more water would make it grow faster.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
35 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=220)+13.3/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational cohort design cannot establish causation due to potential unmeasured confounders. In vitro experiments provide mechanistic hypotheses but do not confirm causality in humans. The study only demonstrates associations and correlations.
No Conflicts
No conflicts of interest identified
No conflicts of interest are disclosed or apparent from the text.
The study lacks explicit conflict of interest and funding statements. The authors' affiliations are not provided, and only institutional ethical approval is noted.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr. William Wallace cite this study, drawing 1 claim from it.
- Good evidence
Good evidence supports this claim, with little to contradict it.
Evidence